The ticking clock behind clinical trial validation

For a global life sciences organization managing complex clinical trial operations, Food and Drug Administration (FDA) inspections often came with a preparation window of only 2 to 3 business days to demonstrate complete site compliance. Under the company’s legacy operating model, that narrow timeline exposed several operational bottlenecks:

Manual data reconciliation: Quality assurance teams spent hours extracting data and reconciling audit trails from critical GxP records spread across electronic data capture (EDC) systems, electronic trial master file (eTMF) platforms, clinical trial management systems (CTMS), Veeva Vault, and other disconnected applications.
Limited visibility across regulatory data: Fragmented records created blind spots that allowed micro-deviations across production batches, disconnected training records, and timestamp inconsistencies to go undetected until regulatory inspections.
Challenges with end-to-end traceability: During annual product quality reviews (APQRs), limited system-wide visibility made it difficult to provide the data lineage regulators expected and manage compliance activities at scale.

Left unresolved, these challenges increased regulatory and compliance risks.

The organization had previously partnered with Virtusa on a focused, 11-week proof of concept (PoC) that demonstrated the potential of AI-driven inspection preparedness. Building on that success, Virtusa scaled the solution into a production-grade framework for live quality workflows.

2–3 days

14

70%

80%

60%

Services

Industries

Insights

Careers

About